C. Leonetti et al., Encapsulation of c-myc antisense oligodeoxynucleotides in lipid particles improves antitumoral efficacy in vivo in a human melanoma line, CANC GENE T, 8(6), 2001, pp. 459-468
Phosphorothioate c-myc antisense oligodeoxynucleotides [S]ODNs (free INX-62
95) were encapsulated in a new liposome formulation and the antitumor activ
ity was compared to the unencapsulated antisense in a human melanoma xenogr
aft. The systemic administration of INX-6295 encapsulated in stabilized ant
isense lipid particles (SALP INX-6295) improved plasma AUC (area under the
plasma concentration -time curve) and initial half-life of free INX-6295, r
esulting in a significant enhancement in tumor accumulation and improvement
in tumor distribution of antisense oligodeoxynucleotides. Animals treated
with SALP INX-6295 exhibited a prolonged reduction of c-myc expression, red
uced tumor growth and increased mice survival. When administered in combina
tion with cisplatin (DDP), SALP INX-6295 produced a complete tumor regressi
on in approximately 30% of treated mice, which persisted for at least 60 da
ys following the first cycle of treatment. Finally, the median survival of
mice treated with DDP/SALP INX-6295 increased by 105% compared to 84% for a
nimals treated with the combination DDP/free INX-6295. These data indicate
that the biological activity and the therapeutic efficacy of c-myc antisens
e therapy may be improved when these agents are administered in lipid-based
delivery systems.